Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

NCT00918450 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor has decided to not proceed with this study.

Conditions

B-cell Chronic Lymphocytic Leukemia

Interventions

DRUG: ABT-263

Sponsor

Abbott

Collaborators

[object Object]